CStone Pharmaceuticals

基石藥業

(Incorporated in the Cayman Islands with limited liability)

(**Stock Code: 2616**)

VOLUNTARY ANNOUNCEMENT
CSTONE ANNOUNCED POSITIVE GAVRETO® REGISTRATIONAL STUDY DATA FOR FIRST-LINE TREATMENT OF ADVANCED RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER AND PLANS TO SUBMIT A NEW INDICATION APPLICATION

CStone Pharmaceuticals (the "**Company**" or "**CStone**") is pleased to announce data from a China registrational study of the global pivotal Phase 1/2 ARROW trial of GAVRETO® (pralsetinib). The results demonstrated deep and durable clinical activity of GAVRETO® (pralsetinib) for the first-line treatment of Chinese patients with advanced rearranged during transfection ("**RET**") fusion-positive non-small cell lung cancer ("**NSCLC**"), which is consistent with the global population. The overall safety is manageable, no new safety signal detected. GAVRETO is a potent and selective RET inhibitor discovered by CStone's partner Blueprint Medicines Corporation (NASDAQ: BPMC) ("**Blueprint Medicines**").

Key Highlights

- Key efficacy data showed that GAVRETO® demonstrated deep and durable clinical activity in Chinese patients with RET fusion-positive NSCLC, which strengthens CStone's leading position in the field of lung cancer

- CStone plans to submit new indication application to China National Medical Products Administration ("**NMPA**") for GAVRETO® as a first-line treatment for patients with RET fusion-positive NSCLC

- As the first selective RET inhibitor in China, GAVRETO® has been approved and available in China market. Following the success of sugemalimab as the world's first anti-PD-1/PD-L1 monoclonal antibody covering both stage III and stage IV NSCLC patients, and the joint development of ROS1 target therapy lorlatinib with Pfizer, CStone is becoming a dominant player in precision treatment and immunotherapy for lung cancer

Professor Yi-long Wu of Guangdong Provincial People's Hospital, and Principal Investigator on the ARROW study China cohort, said, "Platinum-based chemotherapy is recommended as the standard first-line treatment for patients with RET fusion-positive NSCLC in mainland China, but there is a need for new treatment options. The initial approval of GAVRETO® in mainland China heralds a new era for RET inhibitors in the treatment of RET fusion-positive NSCLC after platinum-based chemotherapy. With the promising data shown in the registrational study where GAVRETO® is studied as a potential first-line treatment for Chinese patients with RET fusion-positive NSCLC, we very much look forward to the potential approval of broader indications in mainland China."

Dr. Jason Yang, Chief Medical Officer of CStone, said, "We are glad to see that the registrational study of GAVRETO® for the first-line treatment of RET fusion-positive NSCLC patients in mainland China has shown promising efficacy results and safety is manageable, adding more clinical evidence for GAVRETO®. We would like to thank all the investigators, patients and their families involved in this clinical study. We will initiate regulatory discussions with the NMPA and look forward to potentially benefiting more patients soon."

CStone plans to submit new indication application to the NMPA for GAVRETO® as a first-line treatment for patients with RET fusion-positive NSCLC soon. Detailed study data will be presented at a future international academic conference.

In March 2021, GAVRETO® was granted a new drug approval by the NMPA as mainland China's first selective RET inhibitor for the treatment of adult patients with locally advanced or metastatic RET fusion-positive NSCLC after platinum-based chemotherapy. The first batch of prescriptions was issued across multiple cities in mainland China in June 2021, benefiting Chinese patients. Additionally, in the recently published "2021 Clinical Guidelines for Molecular Pathological Detection of NSCLC," RET testing was granted a recommendation for the detection of RET fusion-positive NSCLC patients. GAVRETO® was included in the 2021 Chinese Medical Association guidelines for clinical diagnosis and treatment of lung cancer as the only recommended second-line or later therapy for RET fusion-positive stage IV non-squamous NSCLC that has progressed following platinum-based chemotherapy. In April 2021, the NMPA accepted the supplemental New Drug Application of GAVRETO® with priority review designation for the treatment of patients with advanced or metastatic RET-altered thyroid cancers. Following a regulatory review by the NMPA, the labeled indications for GAVRETO in mainland China may be expanded to include advanced or metastatic RET-mutant medullary thyroid cancer ("**MTC**") who require systemic therapy, and advanced or metastatic RET fusion-positive thyroid cancers who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate), if approved.

CStone has an exclusive collaboration and license agreement with Blueprint Medicines for the development and commercialization of GAVRETO in Greater China, which encompasses mainland China, Hong Kong, Macau, and Taiwan.

About the ARROW Study

The ARROW study is a global phase I/II clinical study designed to evaluate the safety, tolerability and efficacy of GAVRETO in patients with RET fusion-positive NSCLC, RET-mutant MTC and other advanced solid tumors with RET fusions.

Data from the ARROW study were presented at the IASLC 2020 World Conference on Lung Cancer ("**WCLC**"). As of data cutoff date of May 22, 2020, the results showed that GAVRETO had robust and durable anti-tumor activity in Chinese patients with advanced or metastatic RET fusion-positive NSCLC after platinum-based chemotherapy. In 32 patients who had measurable disease at baseline, the confirmed overall response rate ("**ORR**") was 56%, the median duration of response ("**DOR**") was not

reached, and the six-month DOR rate was 83%. GAVRETO was well-tolerated, and there were no adverse events related to treatment with GAVRETO that led to treatment discontinuation or death.

About RET fusion-positive NSCLC

In recent years, mainland China has had rising lung cancer incidence. According to the latest estimates on the global burden of cancer released by International Agency for Research on Cancer ("**IARC**"), in 2020, an estimated 0.82 million new lung cancer cases and 0.71 million new lung cancer deaths occurred in China. Among all Chinese cancer patients, lung cancer is the leading cause of cancer-related deaths. NSCLC is the most common type of lung cancer.

In lung cancer, there are a number of somatic mutations, including EGFR, ALK, and ROS1, that can be targeted with approved therapies. RET fusions account for 1-2% of NSCLC patients, the majority of whom are non-smokers.

About GAVRETO® (pralsetinib)

GAVRETO® (pralsetinib) is a once-daily oral targeted therapy approved by the NMPA for the treatment of adults patients with locally advanced or metastatic RET fusion-positive NSCLC after platinum-based chemotherapy.

GAVRETO™ is approved by the U.S. Food and Drug Administration ("**FDA**") for the treatment of three indications: adult patients with metastatic RET fusion-positive NSCLC as detected by an FDA approved test, adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant MTC, and adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). These indications are approved under accelerated approval based on ORR and DOR. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials.

Pralsetinib is not approved for the treatment of any other indication in mainland China by the NMPA or in the U.S. by the FDA, or for any indication in any other jurisdiction by any other health authority.

Pralsetinib is designed to selectively and potently target oncogenic RET alterations, including secondary RET mutations predicted to drive resistance to treatment. In preclinical studies, pralsetinib inhibited RET at lower concentrations than other pharmacologically relevant kinases, including VEGFR2, FGFR2, and JAK2.

Blueprint Medicines and Roche are co-developing pralsetinib globally (excluding Greater China) for the treatment of patients with RET-altered NSCLC, thyroid cancer, and other solid tumors. Blueprint Medicines and Genentech, a member of the Roche Group, are co-commercializing GAVRETO in the U.S., and Roche has exclusive commercialization rights for GAVRETO outside of the U.S. (excluding greater China). The European Medicines Agency validated a marketing authorization application for pralsetinib for the treatment of RET fusion-positive NSCLC, and the review is ongoing. The FDA granted breakthrough therapy designation to pralsetinib for the treatment of RET fusion-positive NSCLC that has progressed following platinum-based chemotherapy and for RET mutation-positive MTC that requires systemic treatment and for which there are no alternative treatments.

About CStone

CStone is a biopharmaceutical company focused on researching, developing and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and worldwide. Established in 2015, CStone has assembled a world-class management team with extensive

experience in innovative drug development, clinical research, and commercialization. The Company has built an oncology-focused pipeline of 15 drug candidates with a strategic emphasis on immuno-oncology combination therapies. Currently, CStone has received three drug approvals in Greater China, including two in mainland China and one in Taiwan. CStone's vision is to become globally recognized as a world-renowned biopharmaceutical company by bringing innovative oncology therapies to cancer patients worldwide.

For more information about CStone, please visit: www.cstonepharma.com.

By Order of the Board
CStone Pharmaceuticals
Dr. Frank Ningjun Jiang
Chairman

Suzhou, People's Republic of China, June 24, 2021

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Frank Ningjun Jiang as Chairman and executive Director, Dr. Wei Li, Mr. Qun Zhao, Mr. Yanling Cao, Mr. Xianghong Lin and Dr. Lian Yong Chen as non-executive Directors, and Dr. Paul Herbert Chew, Mr. Ting Yuk Anthony Wu and Mr. Hongbin Sun as independent non-executive Directors.